NASDAQ:RPTX
Repare Therapeutics Inc. Stock News
$3.18
-0.0600 (-1.85%)
At Close: Jul 03, 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI.
BOSTON--(BUSINESS WIRE)--Foundation Medicine announces a collaboration with Repare Therapeutics to provide genomic profiling for Repare's ongoing Phase I/Ib MYTHIC study.
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
07:05am, Monday, 10'th Jun 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the firs
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
11:01am, Thursday, 06'th Jun 2024
Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S.
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Monday, 03'rd Jun 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that mem
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
07:05am, Wednesday, 29'th May 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data f
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
04:05pm, Tuesday, 07'th May 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial
LAUSANNE, Switzerland & MONTREAL--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure ca
MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www
Repare Therapeutics Appoints Steven H. Stein, M.D.
04:05pm, Friday, 26'th Apr 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appo
NEW YORK--(BUSINESS WIRE)---- $RPTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Rep
NEW YORK--(BUSINESS WIRE)---- $RPTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Rep
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
08:00pm, Monday, 11'th Mar 2024
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are ad
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTX
12:15pm, Tuesday, 05'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning poss
